Lung Structure-Function In Survivors of Mild and Severe COVID-19 Infection

Condition(s) studied

Investigational drug(s) / intervention(s)

Hyperpolarized Xenon-129 MRI of the lungs: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas

Computed Tomography (CT): Participants will undergo a CT scan of the thoracic cavity

Pulmonary Function Tests (PFT): Participants will have their lung function evaluated using PFT

Six Minute Walk Test (6MWT): Participants will perform the six minute walk test as a measure of exercise capacity

Sputum analysis: Participants will provide a sputum sample that will be analysed for eosinophils

Blood analysis: Participants will have their blood drawn and analysed for eosinophil count.

Questionnaires: Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.

Study summary

This is a longitudinal study of the long-term impact of COVID-19 on the lungs. Participants will be followed over a period of up to 4 years and impacts of COVID-19 on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129, pulmonary function tests, exercise capacity, computed tomography imaging and questionnaires.

Eligibility

Primary outcome measure(s)

• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by VDP. — 1 year
  Measured using 129-Xenon MRI ventilation defect percent
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FEV1. — 1 year
  Measured using forced expiratory volume in one second (FEV1)
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FVC. — 1 year
  Measured using forced vital capacity (FVC)
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by TLC. — 1 year
  Measured using total lung capacity (TLC)
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FRC. — 1 year
  Functional residual capacity (FRC)
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by RV. — 1 year
  Measured using residual volume (RV)
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FOT. — 1 year
  Measured using forced oscillation technique (FOT)
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by LCI. — 1 year
  Measured using lung clearance index (LCI)
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FeNO. — 1 year
  Measured using Fractional Exhaled Nitric Oxide (FeNO).
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by exercise capacity. — 1 year
  Exercise capacity measured by six-minute walk test
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by baseline dyspnea index questionnaire — 1 year
  Measured using the baseline dyspnea index questionnaire.
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by (mMRC) dyspnea scale questionnaire. — 1 year
  Measured using the modified medical research council (mMRC) dyspnea scale questionnaire.
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by CAT. — 1 year
  Measured using the COPD assessment test (CAT).
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by SGRQ. — 1 year
  Measured using the St. George's respiratory questionnaire (SGRQ).
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by IPAQ. — 1 year
  Measured using the International Physical Activity Questionnaire (IPAQ).
• Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by eosinophil count. — 1 year
  Measured using blood and sputum eosinophil count.

Trial sites (1)

More Western University, Canada trials in Canada

Other trials for the same condition